# A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

> **NCT04962724** · PHASE1 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Radiolabelled Xevinapant 200 mg (Oral Solution)
- **DRUG:** Radiolabelled Xevinapant 100 μg (IV Solution)
- **DRUG:** Xevinapant 200 mg (Oral Solution)

## Key facts

- **NCT ID:** NCT04962724
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-02
- **Primary completion:** 2021-11-09
- **Final completion:** 2021-11-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04962724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04962724, "A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04962724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*